MARKET

NIKI

NIKI

NIKI BIOSOLUTIONS INC,
NASDAQ
8.83
+1.83
+26.14%
After Hours: 7.80 -1.03 -11.66% 19:59 07/20 EDT
OPEN
11.00
PREV CLOSE
7.00
HIGH
12.24
LOW
7.01
VOLUME
956.00K
TURNOVER
--
52 WEEK HIGH
44.70
52 WEEK LOW
6.00
MARKET CAP
7.19M
P/E (TTM)
-4.7627
1D
5D
1M
3M
1Y
5Y
1D
NASDAQ TRADE HALT <NIKI.O> VOLATILITY TRADING PAUSE AT 09:31 AM
Reuters · 13h ago
NASDAQ TRADE HALT <NIKI.O> NEWS AND RESUMPTION TIMES AT 09:00 AM
Reuters · 13h ago
Aptorum Group plans 1-for-10 reverse stock split ahead of DiamiR merger
PUBT · 14h ago
Weekly Report: what happened at APM last week (0713-0717)?
Weekly Report · 16h ago
Upcoming Stock Splits This Week (July 20 to July 24) – Stay Invested
TipRanks · 1d ago
Aptorum Group Ltd trading halted, news pending
TipRanks · 3d ago
Aptorum provide update on DiamiR merger, announces 1-for-10 reverse stock split
TipRanks · 4d ago
Aptorum Group Announces 1-For-10 Reverse Stock Split, Effective July 20; Proposed Merger With DiamiR Biosciences Anticipated To Close Around July 20
Benzinga · 4d ago
More
About NIKI
Aptorum Group Limited is a United Kingdom-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.

Webull offers Aptorum Group Ltd stock information, including NASDAQ: NIKI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NIKI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NIKI stock methods without spending real money on the virtual paper trading platform.